{"id":"fenoldopam-mesilate","safety":{"commonSideEffects":[{"rate":"3-5","effect":"Tachycardia"},{"rate":"3-5","effect":"Headache"},{"rate":"1-3","effect":"Dizziness"},{"rate":"1-3","effect":"Nausea"},{"rate":"1-3","effect":"Flushing"},{"rate":"1-3","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fenoldopam selectively binds to dopamine-1 receptors on vascular smooth muscle and renal vasculature, leading to peripheral and renal vasodilation. This results in decreased systemic vascular resistance, lowered blood pressure, and improved renal perfusion. It is used primarily for acute hypertension management in hospital settings.","oneSentence":"Fenoldopam mesilate is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:30.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute hypertension in hospitalized patients"},{"name":"Hypertensive crisis"}]},"trialDetails":[{"nctId":"NCT01073189","phase":"PHASE4","title":"Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury","status":"WITHDRAWN","sponsor":"Southeast Renal Research Institute","startDate":"2010-04","conditions":"Kidney Failures, Acute","enrollment":""},{"nctId":"NCT00286403","phase":"PHASE2, PHASE3","title":"Vasodilators and Anti-Oxidant Therapy in Early ATN","status":"WITHDRAWN","sponsor":"Southeast Renal Research Institute","startDate":"2008-08","conditions":"Acute Renal Failure","enrollment":""},{"nctId":"NCT00747331","phase":"PHASE4","title":"Fenoldopam and Splanchnic Perfusion During Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"IRCCS Policlinico S. Donato","startDate":"2008-09","conditions":"Cardiac Complications, Cardiopulmonary Bypass","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DRUG INEFFECTIVE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Corlopam"],"phase":"marketed","status":"active","brandName":"Fenoldopam mesilate","genericName":"Fenoldopam mesilate","companyName":"IRCCS Policlinico S. Donato","companyId":"irccs-policlinico-s-donato","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fenoldopam mesilate is a selective dopamine-1 (DA1) receptor agonist that causes vasodilation and increases renal blood flow. Used for Acute hypertension in hospitalized patients, Hypertensive crisis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}